CN108558798A - A kind of drug for treating depression - Google Patents
A kind of drug for treating depression Download PDFInfo
- Publication number
- CN108558798A CN108558798A CN201810533778.7A CN201810533778A CN108558798A CN 108558798 A CN108558798 A CN 108558798A CN 201810533778 A CN201810533778 A CN 201810533778A CN 108558798 A CN108558798 A CN 108558798A
- Authority
- CN
- China
- Prior art keywords
- formula
- added
- drug
- disease
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 FC(c1c*c(C=C[C@@](C2)C=CC=C2I)cc1)(F)F Chemical compound FC(c1c*c(C=C[C@@](C2)C=CC=C2I)cc1)(F)F 0.000 description 1
- GBBCZSRFCBRNBA-SNAWJCMRSA-N [O-][N+](c1cc(/C=C/c2ccc(C(F)(F)F)cc2)ccc1)=O Chemical compound [O-][N+](c1cc(/C=C/c2ccc(C(F)(F)F)cc2)ccc1)=O GBBCZSRFCBRNBA-SNAWJCMRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of drug for treating depression,Wherein:R1、R2、R3It is independently selected from H, F or OCH3.In recent years, 5 hydroxytryptamine reuptakes of 5 hydroxytryptamine 1A acceptor portions excitements and selectivity inhibit the antidepressants of double action to have become the hot spot direction that newly-developed antidepressant is studied.In synaptosomes in rat brain in vivo to [3H] 5 HT intake inhibiting effect is tested and h5 HT1AConfirm that the compounds of this invention has 5 HT reuptake inhibitions and to 5 HT in binding affinity experiment1AReceptor has agonism, illustrates that the compound of the present invention can be as the drug for the treatment of mankind's central nervous system dysfunction such as depression, anxiety disorder.
Description
Technical field
The invention belongs to chemical medicines, are related to a kind of drug for treating depression.
Background technology
Depression (depressive disorder) is the psychiatric barrier of high pathogenicity rate, high disability rate and high homicide rate
Hinder, has become serious society and public health problem at present.Clinically common antidepressants such as serotonin reuptake transporter
One lines such as inhibitor (Selective serotonin reuptake inhibitors, SSRIs) class antidepressant Prozac
Drug generally existing effective percentage is high, work slowly, sex dysfunction, many defects such as lead to introgression.In recent years, 5- hydroxyls
Tryptamines 1A acceptor portions excitement and selective serotonin reuptake inhibit the antidepressants (serotonin of double action
Partial agonist and reuptake inhibitors, SPARIs), it dives because it has stronger curative effect and quick acting etc.
In feature and the extremely low advantage of adverse reaction (including sex dysfunction and weight gain etc.) incidence, it has also become novel anti-
The hot spot direction of depressed drug research.
The compound of the present invention can effectively inhibit 5-HT reuptakes and to 5-HT1AReceptor has agonism, the present invention
Compound can as treatment mankind's central nervous system (CNS) dysfunction such as depression, anxiety disorder drug.
Invention content
The invention discloses a kind of Formula I, structure is:
Wherein:R1、R2、R3Be independently selected from H, F or
OCH3.The invention further relates to the pharmaceutically acceptable salt of the Formula I or solvates.
Further, Formula I described in some preferred schemes is
The synthetic route that another object of the present invention discloses the Formula I is:
Specifically synthetic method is:
1) under cryogenic, using DMF as solvent, nitrobenzene and suitable inorganic base are stirred at low temperature, will be dissolved in
Iodine in DMF is added drop-wise in reaction, through subsequent processing after the reaction was complete, you can obtains the iodo- 3- nitrobenzenes of light yellow solid 1-;
2) using DMF as solvent, by the iodo- 3- nitrobenzenes of 1- obtained in the previous step and 1- (trifluoromethyl) -4- vinyl benzenes, N,
N- diisopropylethylamine, tri-o-tolyl phosphorus and palladium catalyst are placed in reaction bulb, are heated to 100 DEG C of reactions under nitrogen protection
To the reaction was complete, (E) -1- nitros -3- (4- (trifluoromethyl) styryl) benzene can be obtained through subsequent processing within 12 hours;
3) (E) -1- nitros -3- (4- (three obtained in the previous step then will be added after ethyl alcohol, water and ammonium chloride stirring and dissolving
Methyl fluoride) styryl) benzene, iron powder is then added, heating makes it, and the reaction was complete, and light yellow solid (E) -3- is obtained through subsequent processing
(4- (trifluoromethyl) styryl) aniline;
4) it 1. is cooled to 0 DEG C by after sodium nitrite in water stirring and dissolving, (E) -3- (4- (fluoroforms that will be previously obtained
Base) styryl) aniline is dissolved in glacial acetic acid, and it is then added drop-wise in reaction bulb and stirs 1 hour;2. HCl solution is added dropwise at 0 DEG C;
3. dichloromethane is added in stirring at 0 DEG C, by potassium iodide and iodine it is soluble in water after be added drop-wise in system at 0 DEG C, equality of temperature stirring 2
Hour to the reaction was complete, obtains the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene after subsequent processing;
5) the iodo- 3- of (E) -1- being previously obtained (4- (trifluoromethyl) styryl) benzene is dissolved in suitable polar solvent
In, under nitrogen protection, [1,1 '-bis- (diphenylphosphine) ferrocene] palladium chloride dichloromethane complex, cesium carbonate, two are added
Chloromethanes and corresponding mercaptan are then heated to 80 DEG C, and reaction obtains final for 16 hours to the reaction was complete after subsequent processing
Product.
Further, the inorganic base in the step 1) can be potassium carbonate, sodium carbonate, sodium bicarbonate, cesium carbonate etc., excellent
Select potassium carbonate.
Further, palladium catalyst can be PdCl in the step 2)2, Pd (OAc)2, Pd (dppf) Cl2It is preferred that chlorination
Palladium.
Further, polar solvent can be DMF, n,N-dimethylacetamide, N, N- diethyl first in the step 5)
Amide, N, N- diethyl acetamides etc., preferably DMF.
Another object of the present invention discloses the Formula I and its pharmaceutically acceptable salt and/or solvate
As 5-HT reuptaking inhibitors and/or 5-HT1AThe application of receptor stimulating agent.
Another object of the present invention discloses the Formula I and its pharmaceutically acceptable salt and/or solvate
Application in the drug for preparing central nervous system dysfunction disease.
The compound and pharmaceutical composition provided by the invention can be used for preparing dynamic for preventing, treating or mitigating lactation
Object includes the drug of the central nervous system dysfunction of the mankind, can be used for prepare for inhibit 5-HT reuptakes and/or
Exciting 5-HT1AThe drug of receptor.
Specifically, the amount of compound effectively detectably can selectively inhibit 5-HT in the composition of the present invention
Reuptake and to 5-HT1AReceptor has agonism, the compound of the present invention that can be used as treatment mankind's central nervous system (CNS)
The drug of dysfunction such as depression, anxiety disorder.
The compound of the present invention can be applied to, but be not limited to, and use the effective of the compound of the present invention or composition
Amount administers to a patient to prevent, treat or mitigate mammal, includes the central nervous system dysfunction disease of the mankind.Institute
The central nervous system dysfunction disease of the mankind in response to 5-HT receptor modulators stated further comprises but and unlimited
In, depression, anxiety disorder, mania, schizophrenia, sleep disturbance, bipolar disorders, besetment and behavior disorder, in terror
Obstacle, posttraumatic stress disorder, dyskinesia, sex dysfunction, musculoskeletal pain obstacle, cognitive disorder, memory disorders, pa
Golden Sen Shi diseases, Huntington's disease, phobia, substance abuse or habituation, drug addiction withdrawal symptom and premenstrualtension syndrome
Deng.
Pharmaceutically acceptable salt of the present invention refers to the organic salt and inorganic salts of the compounds of this invention.Pharmaceutically may be used
The salt that the nontoxic acid received is formed includes, but is not limited to, inorganic acid salt, such as hydrochloride, hydrobromate, phosphate, sulfuric acid
Salt, perchlorate;Acylate, such as acetate, oxalates, maleate, tartrate, citrate, succinate, the third two
Hydrochlorate;Or these salt are obtained by other methods described in the books or literature such as ion-exchange.Other can pharmaceutically connect
The salt received includes adipate, alginates, ascorbate, aspartate, benzene sulfonate, benzoate, bisulphate,
Borate, butyrate, camphor hydrochlorate, camsilate, cyclopentyl propionate, digluconate, lauryl sulfate, second
Sulfonate, formates, fumarate, gluceptate, glycerophosphate, gluconate, Hemisulphate, enanthate,
Caproate, hydriodate, 2- hydroxy-ethanesulfonate salts, lactobionate, lactate, laruate, lauryl sulfate, apple
Hydrochlorate, mesylate, 2- naphthalene sulfonates, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfuric acid
Salt, 3- phenylpropionic acid salt, picrate, pivalate, propionate, stearate, rhodanate, tosilate, 11
Hydrochlorate, valerate, etc..By including alkali metal, alkaline-earth metal, ammonium and N+ (C1-4 alkane with alkali appropriate salt obtained by the reaction
Base) 4 salt.Water-soluble or oil-soluble or dispersion product can be obtained by quaternization.Can with the alkali metal of forming salt or
Alkaline-earth metal includes sodium, lithium, potassium, calcium, magnesium, etc..Pharmaceutically acceptable salt further comprises appropriate, nontoxic ammonium, season
The amine cation that ammonium salt and gegenions are formed, such as halide, hydroxide, carboxylate, hydrosulphate, phosphoric acid compound, nitre
Acidulants, C1-8 azochlorosulfonate acid compounds and aromatic sulphonic acid compound.
Solvate of the present invention refers to that one or more solvent molecules are formed by with the compound of the present invention and form
Close object.The solvent for forming solvate includes, but is not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, ethyl acetate,
Acetic acid and ethylaminoethanol.
Specific embodiment
Embodiment 1:(E) synthesis of -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulfenyl) furans
The synthesis of the iodo- 3- nitrobenzenes of 1-1,1-:
The DMF of 70mL is added in 500mL reaction bulbs, nitrobenzene (30.12g, 0.245mol) and potassium carbonate is then added
(25.2g, 0.182mol) is cooled down in 10 DEG C or less ice baths, after stirring, is added drop-wise to after iodine (0.250mol) is dissolved in 30mLDMF
In reaction system, time for adding is 1 hour, and reaction mixture is stirred 16 hours to the reaction was complete at 25 DEG C, is added thio
The aqueous solution (150mL) of sodium sulphate (22.3g, 0.141mol) and potassium carbonate (0.150g), while maintaining interior 30 DEG C of temperature hereinafter, stirring
It mixes 30 minutes, is added with stirring water 200mL, solid is precipitated, and filters, and filter cake is washed with water, and 60 DEG C are dried in vacuo 12 hours, obtain pale yellow
The iodo- 3- nitrobenzenes of color solid 1-, 43.84g, yield 72%.1H-NMR(400MHz,CDCl3)δ:7.35(t,1H),8.15(d,
1H),8.20(d,1H),8.31(s,1H).13C-NMR(125MHz,CDCl3)δ:96.89,125.46,130.70,131.26,
144.68,148.36.LC-MS(ESI,pos,ion)m/z:250[M+H].
The synthesis of 1-2, (E) -1- nitros -3- (4- (trifluoromethyl) styryl) benzene:
The DMF of 200mL is added in 500mL reaction bulbs, the iodo- 3- nitre of 1- that synthesis step 1-1 is synthesized then is added
Base benzene (43.84g, 0.176mol), 1- (trifluoromethyl) -4- vinyl benzenes (0.176mol), n,N-diisopropylethylamine
(20.5g, 0.159mol), tri-o-tolyl phosphorus (2.23g, 0.0073mol) and palladium bichloride (0.49g, 0.0028mol), in nitrogen
100 DEG C of reactions are heated under gas shielded, and extremely the reaction was complete within 12 hours, is cooled to 45 DEG C, isopropanol 100mL is added, is stirred at 45 DEG C
It mixes 30 minutes, is diluted with 500mL water, stirred 1 hour at room temperature, filter, be washed with water, filter cake is added in 120mL isopropanols,
It stirs 30 minutes, is then stirred at room temperature 30 minutes at 55 DEG C, filter, filter cake is washed with cold isopropanol, 50 DEG C of vacuum
It is 12 hours dry, obtain (E) -1- nitros -3- (4- (trifluoromethyl) styryl) benzene, 48.52g, yield 94.0%, fusing point
175~176 DEG C.1H-NMR(400MHz,CDCl3)δ:7.06(d,1H),7.15(d,1H),7.53(d,2H),7.69(d,2H),
7.74(t,2H),7.92(d,1H),8.11(d,1H),8.43(s,1H).13C-NMR(125MHz,CDCl3)δ:123.62,
124.42,124.67,125.45,127.87,127.90,129.14,130.50,131.91,135.09,136.35,139.21,
147.55.LC-MS(ESI,pos,ion)m/z:294[M+H].
The synthesis of 1-3, (E) -3- (4- (trifluoromethyl) styryl) aniline:
Ethyl alcohol 140mL, water 100mL and ammonium chloride (30.0g, 0.561mol), stirring and dissolving are added in 500mL reaction bulbs
Addition (E) -1- nitros -3- (4- (trifluoromethyl) styryl) benzene (48.52g, 0.165mol) afterwards, addition iron powder (16.2g,
0.290mol), 50 DEG C are heated to, is stirred to react 2 hours, until the reaction was complete, 22 DEG C is cooled to, 200mL tetrahydrofurans, room is added
Temperature stirring 1 hour, is filtered by diatomite, and filter cake is washed with tetrahydrofuran, and filtrate rotates to doing, and is cooled to room temperature, adds water
200mL is stirred at room temperature 1 hour, filters, filter cake petroleum ether, and 50 DEG C are dried in vacuo 12 hours, obtain light yellow solid
(E) -3- (4- (trifluoromethyl) styryl) aniline, 38.49g, yield 88.6%.1H-NMR(400MHz,CDCl3)δ:3.65
(s,2H),6.39(d,1H),6.69(s,1H),6.90(d,1H),6.95(d,1H),6.99(d,1H),7.06(t,1H),7.53
(d,2H),7.69(d,2H).13C-NMR(125MHz,CDCl3)δ:113.69,116.37,118.03,123.62,125.45,
127.87,127.90,129.58,130.50,131.91,136.35,139.05,147.70.LC-MS(ESI,pos,ion)m/
z:264[M+H].
The synthesis of 1-4, the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene:
60mL water is added in 500mL reaction bulbs and sodium nitrite (7.02g, 0.102mol), stirring and dissolving are cooled to 0
DEG C, (E) -3- (4- (trifluoromethyl) styryl) aniline (38.49g, 0.146mol) is dissolved in 130mL glacial acetic acid, is then dripped
It is added in reaction bulb, time for adding is 0.5 hour, and the process that is added dropwise maintains interior 0 DEG C of temperature, while stirring 1 hour, is added dropwise at 0 DEG C
HCl solution (concentrated hydrochloric acid 11.2mL, water 20mL), drips off in 10 minutes, and temperature is kept to stir 1 hour, and TLC contact plates track diazol
Reaction of formation (PE:EA=1:1).It is added with stirring 80mL dichloromethane at 0 DEG C;By potassium iodide (20.7g, 0.125mol) and iodine
(0.792g, 0.0031mol) is dissolved in 60mL water, is added drop-wise in system at 0 DEG C, and extremely the reaction was complete within 2 hours for stirring.System is reacted
Liquid is imported into the mixture of 20% hypo solution (200mL) and dichloromethane (80mL), is stirred, and layering, water phase is used
The dichloromethane extraction (2*80mL) of frost, diazomethane mutually merges, and 3mol/L sodium hydroxide solution 0.35L are added dropwise, and adjusts water
Ammonium hydroxide 20mL and water 40mL is added in phase pH=9~12, stirs 30 minutes, and layering, water phase extracts (2*120mL) with dichloromethane,
Organic phase merges, and for revolving to doing, column chromatography purifying obtains the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene,
35.77g yield 65.4%.1H-NMR(400MHz,CDCl3)δ:6.90(d,1H),6.95(d,1H),7.09(t,1H),7.52
(d,1H),7.53(d,2H),7.61(d,1H),7.69(d,2H),7.89(s,1H).13C-NMR(125MHz,CDCl3)δ:
95.66,123.62,125.45,127.87,127.90,129.85,130.50,130.98,131.91,136.35,137.77,
139.09,140.44.LC-MS(ESI,pos,ion)m/z:375[M+H].
The synthesis of 1-5, (E) -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulfenyl) furans:
175mLDMF and the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene are added in 500mL reaction bulbs
The complexing of [1,1 '-bis- (diphenylphosphine) ferrocene] palladium chloride dichloromethane is added in (35.77g, 0.096mol), nitrogen protection
Furans -2- mercaptan is added in object (1.49g, 0.0018mol), cesium carbonate (19.8g, 0.061mol) and dichloromethane 2mL
(0.102mol) is heated to 80 DEG C, and to the reaction was complete, revolving removes DMF, is cooled to room temperature within 16 hours for reaction, and acetic acid second is added
Ester 100mL, water 150mL are stirred 40 minutes, separate organic phase, and salt washing is layered, and organic phase is dried with sodium sulphate, is filtered, rotation
It steams to dry, isolated faint yellow (E) -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulfenyl) furan of flash column chromatography
It mutters, 28.83g, yield 86.7%, 142~143 DEG C of fusing point.1H-NMR(400MHz,CDCl3)δ:6.35(t,1H),6.90(d,
1H),6.95(d,1H),7.01(s,1H),7.14(d,1H),7.16(t,1H),7.23(d,1H),7.31(d,1H),7.44(d,
1H),7.53(d,2H),7.69(d,2H).13C-NMR(125MHz,CDCl3)δ:112.29,113.80,123.62,125.45,
125.79,127.06,127.36,127.87,127.90,128.92,130.50,131.91,134.68,136.35,138.44,
142.85,143.89.LC-MS(ESI,pos,ion)m/z:347[M+H].
Embodiment 2:(E) conjunction of -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulfenyl) -5- methoxyl group furans
At:
175mLDMF and the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene are added in 500mL reaction bulbs
The complexing of [1,1 '-bis- (diphenylphosphine) ferrocene] palladium chloride dichloromethane is added in (35.77g, 0.096mol), nitrogen protection
5- methoxyl groups-furans -2- is added in object (1.49g, 0.0018mol), cesium carbonate (19.8g, 0.061mol) and dichloromethane 2mL
Mercaptan (0.102mol) is heated to 80 DEG C, and to the reaction was complete, revolving removes DMF, is cooled to room temperature within 16 hours for reaction, and second is added
Acetoacetic ester 100mL, water 150mL are stirred 40 minutes, separate organic phase, and salt washing is layered, and organic phase is dried with sodium sulphate, mistake
Filter, revolving to dry, isolated faint yellow (E) -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulphur of flash column chromatography
Base) -5- methoxyl group furans, 29.60g, yield 82%.LC-MS(ESI,pos,ion)m/z:377[M+H].
Embodiment 3:(E) synthesis of -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulfenyl) fluoro- furans of -5-:
175mLDMF and the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene are added in 500mL reaction bulbs
The complexing of [1,1 '-bis- (diphenylphosphine) ferrocene] palladium chloride dichloromethane is added in (35.77g, 0.096mol), nitrogen protection
Fluoro- furans -2- the mercaptan of 5- is added in object (1.49g, 0.0018mol), cesium carbonate (19.8g, 0.061mol) and dichloromethane 2mL
(0.102mol) is heated to 80 DEG C, and to the reaction was complete, revolving removes DMF, is cooled to room temperature within 16 hours for reaction, and acetic acid second is added
Ester 100mL, water 150mL are stirred 40 minutes, separate organic phase, and salt washing is layered, and organic phase is dried with sodium sulphate, is filtered, rotation
It steams to dry, isolated faint yellow (E) -2- ((3- (4- (trifluoromethyl) styryl) phenyl) the sulfenyl) -5- of flash column chromatography
Fluoro- furans, 31.10g, yield 89%.LC-MS(ESI,pos,ion)m/z:365[M+H].
Embodiment 4:(E) conjunction of two fluoro- furans of -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulfenyl) -4,5-
At:
175mLDMF and the iodo- 3- of (E) -1- (4- (trifluoromethyl) styryl) benzene are added in 500mL reaction bulbs
The complexing of [1,1 '-bis- (diphenylphosphine) ferrocene] palladium chloride dichloromethane is added in (35.77g, 0.096mol), nitrogen protection
4,5-, bis- fluoro- furans -2- are added in object (1.49g, 0.0018mol), cesium carbonate (19.8g, 0.061mol) and dichloromethane 2mL
Mercaptan (0.102mol) is heated to 80 DEG C, and to the reaction was complete, revolving removes DMF, is cooled to room temperature within 16 hours for reaction, and second is added
Acetoacetic ester 100mL, water 150mL are stirred 40 minutes, separate organic phase, and salt washing is layered, and organic phase is dried with sodium sulphate, mistake
Filter, revolving to dry, isolated faint yellow (E) -2- ((3- (4- (trifluoromethyl) styryl) phenyl) sulphur of flash column chromatography
Base) bis- fluoro- furans of -4,5-, 28.97g, yield 79%.LC-MS(ESI,pos,ion)m/z:383[M+H].
Test example 1:Compound in synaptosomes in rat brain in vivo to [3H] 5-HT intake inhibiting effect
Under the conditions of 37 DEG C, to buffer solution (6.2mM NaCl, 4.5mM KCl, 2.25mM MgSO4, 1.08mM
NaH2PO4, 2.5mM NaHCO3, 9.9mM glucose, 9 μM of EGTA, 45 μM of ascorbicacid (pH7.4)), synaptosome
(150 μ g) and 0.1 μ Ci [3H] in the mixed system that is formed of serotonin, test compound or positive drug or negative right is added
According to, altogether be incubated 15 minutes.
Imipramine is added 10 as the standard positive drug for inhibiting serotonin intake in above-mentioned identical mixed system
μM imipramine, blocking 5-hydroxytryptamine intake, is incubated 15 minutes under the conditions of 4 DEG C, to measure Basal control activity value.Pass through reality
It tests, tests intake inhibiting value of the imipramine to rat brain synaptosome of various concentration, produce suppression curve.
Sample after incubation passes through glass fibers under vacuum with 96 like cell collectors (Unifilter, Packard)
Filter membrane (GF/B, Packard) fast filtering is tieed up, and is rinsed twice in ice-cold incubation buffer, is dissociated to elimination
[3H] serotonin.Dry filter membrane, in scintillation counter (Topcount, Packard), with scintillation solution (Microscint0,
Packard remaining radioactivity) is calculated.Experimental result with relative to control group [3H] serotonin intake suppression percentage
It indicates.
The SERT transporters inhibiting effect of synaptosomes in rat brain in vivo by [3H] concentration of 5-HT weighs.Test-compound needs
It in the case of concentration is more than 6log, at least tests twice, data carry out nonlinear regression analysis through Hill equation curves, obtain IC50Value.
As a result referring to table 1.
1 the compounds of this invention of table in synaptosomes in rat brain in vivo to [3H] 5-HT intake inhibiting effect
Experimental result shows, the compounds of this invention to [3H] 5-HT reuptakes have preferable inhibitory activity, can conduct
5-HT reuptaking inhibitors carry out more in-depth study.
Test example 2:h5-HT1ABinding affinity is tested
Under the conditions of 22 DEG C, to people's HEK-293 cell membrane homogenates, 36 μ g albumen, 0.3nM [3H] 8-OH-DPAT
(Perkin-Elmer) and buffer solution (50mM Tris-HCl (pH7.4), 10mM MgSO4, 0.5mM EDTA, 2 μ g/ml
Aprotinine) in the mixed system formed, it is added or is added without test compound, is incubated 60 minutes altogether.
Standard reference compound is 8-OH-DPAT, and in the mixed system of above-mentioned condition, 10 μM of 8-OH-DPAT are added,
For measuring non-specific binding value.By the data of the 8-OH-DPAT of different experiments test series concentration, obtain competitive bent
Line.
Sample after incubation is with 96 like cell collectors (Unifilter, Packard) under vacuum by pre- dipped
Glass fiber filter (GF/B, Packard) fast filtering of 0.3%PEI, and rushed repeatedly using ice-cold 50mM Tris-HCl
It washes several times.Dry filter membrane, in scintillation counter (Topcount, Packard), with scintillation solution (Microscint0,
Packard remaining radioactivity) is calculated.Inhibition hundred of the experimental result to be specifically bound relative to control group radioligand
Divide than indicating.
[3H] 8-OH-DPAT (0.3nM) and 5-HT in people's HEK-293 cells1AThe flicker that the combination experiment of receptor passes through film
Proximity test method is completed.Test-compound needs in concentration to be more than 6log, at least tests three times, data are through the side Hill
Journey curve carries out nonlinear regression analysis, obtains IC50Value, then calculated through ChengPrusoff equations, obtain Ki values.As a result referring to table
2。
2 the compounds of this invention of table is to 5-HT1AThe binding affinity of receptor
Number | Ki(nM) |
HT-F700 | 17 |
HT-F701 | 17 |
HT-F702 | 15 |
HT-F703 | 15 |
HT-F801 | 21 |
HT-F802 | 21 |
HT-F803 | 23 |
HT-F901 | 17 |
HT-F902 | 18 |
HT-F903 | 18 |
Experimental result shows that the compounds of this invention is to 5-HT1AReceptor shows stronger binding affinity, the present invention
Compound has 5-HT1AReceptor stimulating agent acts on, and can be used as 5-HT1AReceptor stimulating agent carries out drug development.
Claims (7)
1. a kind of Formula I, structure are
Wherein:R1、R2、R3It is independently selected from H, F or OCH3。
2. the pharmaceutically acceptable salt or solvate of Formula I as described in claim 1.
3. Formula I as described in claim 1, characterized in that be selected from following compound:
4. the synthetic route of Formula I as described in claim 1 is:
5. Formula I as claimed in claim 1 or 2 is used as 5-HT reuptaking inhibitors and/or 5-HT1AReceptor stimulating agent
Using.
6. Formula I as claimed in claim 1 or 2 is in the drug for preparing central nervous system dysfunction disease
Using.
7. application as claimed in claim 6, which is characterized in that the central nervous system dysfunction disease is selected from depression
Disease, anxiety disorder, mania, schizophrenia, sleep disturbance, bipolar disorders, besetment and behavior disorder, panic disorder, wound
Stress disorders, dyskinesia, sex dysfunction, musculoskeletal pain obstacle, cognitive disorder, memory disorders, op parkinson's after wound
Disease, Huntington's disease, phobia, substance abuse or habituation, drug addiction withdrawal symptom and premenstrualtension syndrome.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810533778.7A CN108558798A (en) | 2018-05-29 | 2018-05-29 | A kind of drug for treating depression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810533778.7A CN108558798A (en) | 2018-05-29 | 2018-05-29 | A kind of drug for treating depression |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108558798A true CN108558798A (en) | 2018-09-21 |
Family
ID=63540462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810533778.7A Withdrawn CN108558798A (en) | 2018-05-29 | 2018-05-29 | A kind of drug for treating depression |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108558798A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1858852B1 (en) * | 2005-03-09 | 2009-07-01 | MERCK SHARP & DOHME LTD. | Heteroarylsulfonyl stilbenes as 5-ht2a antagonists |
-
2018
- 2018-05-29 CN CN201810533778.7A patent/CN108558798A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1858852B1 (en) * | 2005-03-09 | 2009-07-01 | MERCK SHARP & DOHME LTD. | Heteroarylsulfonyl stilbenes as 5-ht2a antagonists |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104080769B (en) | Aryl or heteroaryl-substituted compound | |
TWI675840B (en) | Fused pyrimidine compound or salt thereof | |
CN104066718B (en) | Substituted benzene compound | |
KR102534185B1 (en) | Biaryl derivatives, synthesis method thereof and pharmaceutical use thereof | |
TW210339B (en) | ||
TWI827016B (en) | Pyridine derivatives and applications in medicine | |
EA003839B1 (en) | 2-aminopyridines containing fused ring substituents as nos inhibitors | |
AU2003239954A1 (en) | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | |
EP2985283B1 (en) | Anti-angiogenesis compound, intermediate and use thereof | |
RU2191776C2 (en) | Ergoline derivatives, method of their synthesis, pharmaceutical composition | |
TW201002682A (en) | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
CA2611711A1 (en) | Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor | |
TWI518087B (en) | Imidazo(1,2-a)pyridin-7-amine | |
EP3766884B1 (en) | Crystal form and salt type of triazolopyrimidine compound and preparation method therefor | |
CN106458943B (en) | Vortioxetine is synthesized by (2,4- 3,5-dimethylphenyl) (2- iodophenyl) sulfane intermediate | |
CN114174271B (en) | C crystal form and E crystal form of pyrazine-2 (1H) -ketone compound and preparation method thereof | |
MX2011000043A (en) | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists. | |
CA3069602C (en) | Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof | |
CN108570004A (en) | A kind of compound that there is double action to 5-HT and its application in treating depression | |
CN114269723B (en) | D crystal form of pyrazine-2 (1H) -ketone compound and preparation method thereof | |
CN108558798A (en) | A kind of drug for treating depression | |
CN108558754A (en) | A kind of drug for treating depression | |
CN108570000A (en) | A kind of drug for treating depression | |
CN101597280B (en) | Compound used as seven-pass transmembrane protein and based on sag structure | |
CN108484544A (en) | A kind of compound that there is double action to 5-HT and its application in treating depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180921 |
|
WW01 | Invention patent application withdrawn after publication |